Aliskiren: A Novel, Orally Active Renin Inhibitor

Published:Jan, 2010

Aliskiren: A Novel, Orally Active Renin Inhibitor

Mohamed Saleem TS, Jain A1, Tarani P1, Ravi V1, Gauthaman K1

Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet, AP, 1Himalayan Pharmacy Institute, Majhitar, East Sikkim - 737 136, India


Renin-angiotensin-aldosterone systems play a major role in the regulation of human homeostasis mechanism, which are also involved in the development of hypertension and end-organ damage through activation of angiotensin II. Inhibitors of the renin-angiotensin-aldosterone system may reduce the development of end-organ damage to a greater extent than other antihypertensive agents. Aliskiren is the first member of the new class of orally active direct renin inhibitors recently approved by the US Food and Drug Administration for the treatment of hypertension. Aliskiren directly inhibiting the renin and reducing the formation of angiotensin II, which is the most effective mediator involved in the pathogenesis of cardiovascular diseases. The present review mainly focuses on the pharmacodynamics and pharmacokinetics and clinical aspects of aliskiren. In this respect, the review will improve the basic idea to understand the pharmacology of aliskiren, which is useful for the further research in cardiovascular disease.